Studies have shown that expression of PD-L1 on tumor cells may have prognostic significance, and hence pembrolizumab was approved in 2019 as 1st line therapy in HNSCC patients with a CPS of ≥1 (4, 12). Here, CD274 is linked to neoplasm.